Nathan Rice

Stock Analyst at Piper Sandler

(3.02)
# 1,337
Out of 5,113 analysts
60
Total ratings
52.63%
Success rate
9.9%
Average return

Stocks Rated by Nathan Rice

First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $41.17
Upside: +16.59%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $35.11
Upside: +19.62%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $30.51
Upside: +14.72%
Bank First
Oct 23, 2025
Maintains: Neutral
Price Target: $137$142
Current: $132.47
Upside: +7.19%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $77.72
Upside: -4.79%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $128.48
Upside: -34.62%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $157.69
Upside: +24.93%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $22.30
Upside: -59.64%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $700.34
Upside: -37.89%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $271.89
Upside: -14.30%
Initiates: Neutral
Price Target: $83
Current: $39.02
Upside: +112.71%
Initiates: Overweight
Price Target: $15
Current: $20.53
Upside: -26.94%